Fig. 1
Kinase inhibitory profile of pazopanib. The bar graph indicates the kinase inhibitory concentration (IC50—drug concentration at which 50% of the target enzymatic activity is inhibited in a cell-free kinase assay) of pazopanib, as reported by Kumar et al.3 Involvement of kinases in canonical oncogenic processes/pathways is indicated in the table on the left (GO.0001525—angiogenesis; GO.0043410—positive regulation of MAPK cascade; GO.0014068—positive regulation of phosphatidylinositol 3-kinase signaling; GO:0046427—positive regulation of the JAK-STAT cascade; GO.0045740—positive regulation of DNA replication)
